Free Trial

Cellebrite DI Ltd. (NASDAQ:CLBT) Forecasted to Post Q2 2024 Earnings of $0.08 Per Share

Cellebrite DI logo with Business Services background

Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) - Investment analysts at William Blair issued their Q2 2024 earnings estimates for shares of Cellebrite DI in a report released on Tuesday, June 11th. William Blair analyst J. Ho expects that the company will earn $0.08 per share for the quarter. William Blair has a "Outperform" rating on the stock. The consensus estimate for Cellebrite DI's current full-year earnings is $0.33 per share. William Blair also issued estimates for Cellebrite DI's Q3 2024 earnings at $0.09 EPS, Q4 2024 earnings at $0.11 EPS, FY2024 earnings at $0.36 EPS, FY2025 earnings at $0.43 EPS, FY2026 earnings at $0.53 EPS, FY2027 earnings at $0.63 EPS and FY2028 earnings at $0.75 EPS.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its earnings results on Thursday, May 23rd. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.02. The company had revenue of $89.60 million for the quarter, compared to analyst estimates of $85.34 million. Cellebrite DI had a positive return on equity of 417.94% and a negative net margin of 32.57%. The business's revenue was up 25.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.03 EPS.

CLBT has been the topic of a number of other research reports. Needham & Company LLC raised their price target on shares of Cellebrite DI from $13.50 to $14.00 and gave the company a "buy" rating in a report on Friday, May 24th. Bank of America boosted their price target on Cellebrite DI from $12.00 to $13.00 and gave the stock a "buy" rating in a research report on Monday, April 1st. Lake Street Capital began coverage on Cellebrite DI in a report on Friday, April 19th. They set a "buy" rating and a $13.00 price objective on the stock. Craig Hallum lifted their target price on shares of Cellebrite DI from $14.00 to $16.00 and gave the stock a "buy" rating in a report on Monday, April 1st. Finally, JPMorgan Chase & Co. boosted their target price on shares of Cellebrite DI from $12.00 to $14.00 and gave the stock an "overweight" rating in a research report on Friday, May 24th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, Cellebrite DI presently has a consensus rating of "Buy" and an average target price of $13.17.


View Our Latest Report on CLBT

Cellebrite DI Price Performance

CLBT traded down $0.25 during midday trading on Thursday, hitting $12.25. 1,633,935 shares of the company's stock traded hands, compared to its average volume of 932,510. The company has a market cap of $2.52 billion, a PE ratio of -21.55, a price-to-earnings-growth ratio of 1.62 and a beta of 1.48. The stock's fifty day simple moving average is $11.01 and its 200-day simple moving average is $10.19. Cellebrite DI has a one year low of $6.08 and a one year high of $12.67.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Parallel Advisors LLC raised its position in Cellebrite DI by 75.0% in the 4th quarter. Parallel Advisors LLC now owns 3,500 shares of the company's stock valued at $30,000 after purchasing an additional 1,500 shares during the last quarter. Quarry LP acquired a new position in Cellebrite DI during the 4th quarter worth about $36,000. Central Asset Investments & Management Holdings HK Ltd bought a new stake in Cellebrite DI during the 4th quarter worth about $113,000. Hennessy Advisors Inc. acquired a new stake in Cellebrite DI in the 4th quarter valued at about $131,000. Finally, New York State Common Retirement Fund raised its stake in shares of Cellebrite DI by 166.0% in the third quarter. New York State Common Retirement Fund now owns 15,440 shares of the company's stock worth $118,000 after acquiring an additional 9,635 shares during the last quarter. Institutional investors own 45.88% of the company's stock.

About Cellebrite DI

(Get Free Report)

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.

Featured Stories

Should you invest $1,000 in Cellebrite DI right now?

Before you consider Cellebrite DI, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.

While Cellebrite DI currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

CPI News Breakdown: Key Market Moves to Follow
Understanding Oversold Stocks
Inside Pelosi’s Latest Stock Moves

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines